Medicaid Could Save Billions With Most Favored Nation Pricing

Medicaid could achieve substantial cost savings by adopting a "most favored nation" (MFN) pricing model for prescription drugs, according to new research. This pricing strategy would tie the reimbursement rates for drugs to the lowest prices paid by other developed countries. The study, published in JAMA Health Forum, analyzed the potential impact of MFN pricing on Medicare Part D and Medicaid.

Researchers from the University of Pittsburgh School of Pharmacy and the University of Maryland School of Pharmacy simulated the effects of MFN pricing. Their findings indicate that if MFN pricing had been in place in 2020, it could have generated an estimated $27.9 billion in savings across Medicare Part D and Medicaid. Specifically, the simulation projected that Medicaid alone could have saved approximately $10.3 billion in that year.

The proposed MFN model is designed to leverage the purchasing power of the United States to negotiate lower drug prices, aligning with policies explored by the Trump administration. While the concept has faced opposition from the pharmaceutical industry, proponents argue it could significantly reduce drug expenditures for government programs. The study's authors emphasize that these savings are based on a specific MFN framework and that actual savings could vary depending on the final implementation details and the specific basket of countries used for comparison.

The potential for significant savings highlights a key area for policymakers seeking to control healthcare costs. The research provides quantitative estimates that could inform future policy discussions regarding drug pricing negotiations for federal healthcare programs. The study's methodology involved modeling drug prices and expenditures under various MFN scenarios, providing a data-driven perspective on the financial implications of such a policy.